Tag - BCAB

H.C. Wainwright launched coverage of BioAtla (NASDAQ:BCAB) with a “buy” rating and $25 price target. The stock closed at $5.77 on March 18. BioAtla is a clinical-stage biopharmaceutical company developing novel...